XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells - Concepedia

Concepedia

Publication | Open Access

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

DOI Full Paper Access

20

Citations

44

References

2025

Year

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster, Kalli C. Catcott, Naniye Malli Cetinbas, Travis Monnell, Caitlin Routhier, Joshua D. Thomas, Keith W. Bentley, Scott D. Collins,

Clinical Cancer Research

Abstract

These data provide a robust preclinical characterization of XMT-2056 and provide rationale and strategy for its clinical evaluation.

References

	Year	Citations

Page 1